John E (Jack) Bailey, Jr. net worth and biography

John Bailey, Jr. Biography and Net Worth

Mr. Bailey has nearly thirty years of commercial pharmaceutical experience and has an in-depth understanding of healthcare market dynamics and the evolution of value-based healthcare systems in the U.S. He has extensive experience in commercial, government and hospital account management, government affairs and marketing.

Most recently, Mr. Bailey led the GlaxoSmithKline pharmaceuticals and vaccines business in the U.S., with responsibility for commercialization efforts across the company—oncology, immunology/rare disease, respiratory and vaccines portfolios. Earlier in his career, he held various leadership positions at Eli Lilly and Company, including Senior Vice President of the Account-Based Markets Division.

Mr. Bailey was appointed to the G1 Therapeutics Board of Directors in March 2020. He also serves on the board of Emergo Therapeutics and is a past member of the board of directors of PhRMA, the pharmaceutical industry trade association, and the North Carolina Biotechnology Center. He holds an MBA from the University of North Carolina and a B.S. in biology from Hobart College.

How do I contact John E (Jack) Bailey, Jr.?: The corporate mailing address for Mr. Bailey, Jr. and other G1 Therapeutics executives is 700 Park Offices Drive Suite 200, Research Triangle Park NC, 27709. G1 Therapeutics can also be reached via phone at (919) 213-9835 and via email at [email protected]. Learn More on John E (Jack) Bailey, Jr.'s contact information.
Has John E (Jack) Bailey, Jr. been buying or selling shares of G1 Therapeutics?: John E (Jack) Bailey, Jr. has not been actively trading shares of G1 Therapeutics during the last quarter. Learn More on John E (Jack) Bailey, Jr.'s trading history.
Who are G1 Therapeutics' active insiders?: G1 Therapeutics' insider roster includes John Bailey, Jr. (CEO), James Hanson (General Counsel), Rajesh Malik (Insider), and Mark Velleca (Director). Learn More on G1 Therapeutics' active insiders.
Are insiders buying or selling shares of G1 Therapeutics?: In the last year, insiders at the sold shares 10 times. They sold a total of 110,255 shares worth more than $397,880.45. The most recent insider tranaction occured on March, 18th when CFO John W V Umstead sold 6,547 shares worth more than $19,771.94. Insiders at G1 Therapeutics own 8.2% of the company. Learn More about insider trades at G1 Therapeutics.
Information on this page was last updated on 3/18/2024.

John E (Jack) Bailey, Jr. Insider Trading History at G1 Therapeutics

John E (Jack) Bailey, Jr. Buying and Selling Activity at G1 Therapeutics

G1 Therapeutics Company Overview

G1 Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing Trilaciclib that is in Phase 3 clinical trial for 1L metastatic triple negative breast cancer (mTNBC); and Phase 2 clinical trial as an antibody-drug conjugate combination trial in mTNBC, as well as completed Phase 2 clinical trial for Neoadjuvant TNBC and 1L Bladder cancer. The company has a license agreement with Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat various indication in humans; Incyclix for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses; and Simcere Pharmaceutical Co., Ltd for the development and commercialization of trilaciclib in all indications. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.

Today's Range

Now: $3.99

$3.84

$4.05

50 Day Range

MA: $3.72

$2.15

$4.88

2 Week Range

Now: $3.99

$1.08

$5.00

Volume

441,518 shs

Average Volume

1,280,485 shs

Market Capitalization

$208.40 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.73

These AI trades triggered this morning (545% return)

From Prosper Trading Academy | Ad

If you think a market crash is possible in 2024, I don't know why you're not using this yet.

Click Here To Get Your Free Copy